Tesamorelin - 10mg

Tesamorelin - 10mg

Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat.

Benefits

• Proven clinical efficacy
• 37% liver fat reduction in NAFLD
• Selective visceral fat targeting (15-20% reduction)
• Standardized dosing
• Preserved subcutaneous fat